Sanara MedTech amends Q3 2022 8-K to correct CellerateRX facility count from 1,593 to 1,714

Sanara MedTech Inc.

Original filing reported CellerateRX approved in 1,593 facilities as of Sep 30, 2022.
Acquisition of Scendia Biologics added 121 facilities, bringing corrected total to 1,714.
Amendment only revises this specific number; all other disclosures remain unchanged.
No change to financial results or any other operational metrics.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sanara MedTech Inc. reported financial results for quarter ended September 30, 2022.

Period: quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, the Company furnished (i) a press release announcing its financial results for the quarter ended September 30, 2022 (the “Press Release”)

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Sanara MedTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-032353

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.